Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02634216 · ClinicalTrials.gov registry record · NA

Effects of Capros in Patients With Type-1 Diabetes

A NA study of Type I Diabetes, sponsored by Ohio State University.

Completed
Registry status
NA
Development phase
24
Enrollment target
3
Study locations

NCT02634216 is a NA study of Type I Diabetes that has completed, run by Ohio State University. The registered enrollment target is 24 participants. The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02634216, a NA study of Type I Diabetes, has completed, sponsored by Ohio State University.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this 12 week longitudinal study is to test the effect of the dietary supplement, Capros, on blood glycemic index of Type 1 diabetics that have a sensor that provides continuous glucose monitoring (CGM). 20 Type 1 Diabetics will take the Capros supplement for 12 weeks to determine the effect of blood glycemic index. Capros, is a generally safe dietary supplement currently sold over the counter in the United States. Type 1 diabetes also known as juvenile diabetes is commonly diagnosed in children and young adults. Insulin is converted into energy needed for daily living, and with diabetes, insulin is not produced in the body as it should causing many problems. In traditional Indian medicine, the gooseberry Phyllanthus emblica has been used for thousands of years as an effective source of polyphenols and antioxidants. A 12 week longitudinal study to determine the effect of the dietary supplement, Capros, on the blood glycemic index in patients with Type 1 diabetes (T1D).

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Capros

Study Locations (3)

Ohio

  • Carepoint East 543 Taylor Ave. - Columbus
  • Martha Morehouse Medical Plaza 2050 Kenny Road - Columbus
  • Davis Heart and Lung Research Institute - Columbus

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2015-01
Est. Completion 2016-05-25
Phase NA

Sponsor

Ohio State University

552 total trials

What the Registry Record Tells You About NCT02634216

The ClinicalTrials.gov registry entry for NCT02634216 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type I Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Capros is the first listed.

NCT02634216 reports 3 study locations spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT02634216 about?

NCT02634216 is a clinical study titled "Effects of Capros in Patients With Type-1 Diabetes". The purpose of this 12 week longitudinal study is to test the effect of the dietary supplement, Capros, on blood glycemic index of Type 1 diabetics that have a sensor that provides continuous glucose monitoring (CGM). 20 Type 1 Diabetics will take the Capros supplement for 12 weeks to determine the ...

What is the current status of trial NCT02634216?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2015-01. Estimated completion is 2016-05-25.

What conditions does trial NCT02634216 study?

This clinical trial studies the following conditions: Type I Diabetes.

What interventions are being tested in trial NCT02634216?

The interventions under investigation include: Capros (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02634216?

This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02634216 being conducted?

This trial has 3 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type I Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.